Preparation and anti-tumor activity of a novel liposome-loaded drug

doi:10.3969/j.issn.1006-7795.2015.02.004

Journal of Capital Medical University ›› 2015, Vol. 36 ›› Issue (2): 172-177.doi: 10.3969/j.issn.1006-7795.2015.02.004

Previous Articles Next Articles

Preparation and anti-tumor activity of a novel liposome-loaded drug

Lu Xuemei¹, Wang Yuji², Wu Jianhui², Cui Chunying¹

1. Department of Pharmaceutics, School of Chemical Biology and Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China;
2. Department of Medicinal Chemistry, School of Chemical Biology and Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China

Received:2014-12-08 Online:2015-04-21 Published:2015-04-16
Supported by:
This study was supported by Significant New Drugs Creation "Five-year" Plan Special Science and Technology Major(2011ZX09302-007-01).

Abstract

Abstract: Objective To prepare an Arg-Gly-Asp-Phe-fatty alcohol(RGDFOC₁₂) liposomes-loaded 17-allylamino-17-demethoxygeldanamycin(17-AAG). Methods RGDFOC₁₂ liposomes-loaded 17-AAG(RLAs) was prepared by film dispersion method and evaluated by particle size analysis, Zeta potential, encapsulation efficiency, the release in vitro, plasma stability, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT) assay and the anti-tumor activity in vivo. Results The RLAs was stable colloidal dispersion system in spherical shape of (130.6±0.6)nm in diameter and the Zeta potential was (-28.37±1.67)mV. The release of RLAs in vitro showed that the released percentage of RLAs in pH 5.4 is more than that in pH 7.4. The MTT assay proved that RLAs inhibited the proliferation of cancer cells. The anti-tumor assay showed that RLAs inhibited tumor growth and reduced the toxicity. Conclusion The RLAs were prepared by film dispersion method. RLAs showed anti-tumor activity in vivo and good potential in cancer therapy.

Key words: anti-tumor, 17-allylamino-17-demethoxygeldanamycin(17-AAG), Arg-Gly-Asp-Phe-fatty alcohol(RGDFOC₁₂)

CLC Number:

R965.1

Lu Xuemei, Wang Yuji, Wu Jianhui, Cui Chunying. Preparation and anti-tumor activity of a novel liposome-loaded drug[J]. Journal of Capital Medical University, 2015, 36(2): 172-177.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2015.02.004

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2015/V36/I2/172

References

[1] Öyüksel H, Mohanty P S, Rubinstein I. VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin:a novel targeted nanomedicine for breast cancer[J]. Int J Pharm, 2009,365:157-161.
[2] Chandran T, Katragadda U, Teng Q, et al. Design and evaluation of micellar nanocarriers for 17-allyamino-17-demethoxy-geldanamycin(17-AAG)[J]. Int J Pharm, 2010,392:170-177.
[3] 孙维彤,张娜.托氟叮脂质体的研究[J].中国药学杂志,2007,42(6):445-449.
[4] Chiosis G, Vilenchik M, Kim J, et al. Hsp90:The vulnerable chaperone[J]. Drug Discov Today, 2004,9(20):881-888.
[5] Scheibel T, Buchner J. The Hsp90 complex-a super-chaperone machine as a novel drug target[J]. Biochem Pharmcol, 1998,56(6):675-682.
[6] Holzbeierlein J M, Windsperger A, Vielhauer G. Hsp90:A drug target?[J]. Curr Oncol Rep, 2010,12(2):95-101.
[7] Isaacs J S, Xu W, Neckers L.Heat shock protein 90 as a molecular target for cancer therapeutics[J]. Cancer Cell, 2003,3(3):213-217.
[8] Konstantinopoulos P A, Papavassiliou A G. 17-AAG:mechanisms of antitumour activity[J]. Expert Opin Investig Drugs, 2005,14(12):1471-1474.
[9] Saxena V, Naguib Y, Hussain M. Folate receptor targeted 17-allylamino-17-demethoxygeldanamycin(17-AAG) loaded polymeric nanoparticles for breast cancer[J]. Colloids Surf B Biointerfaces, 2012,94:274-280.
[10] Meyer P N, Roychowdhury S, Kini A R, et al. HSP90 inhibitor 17AAG causes apoptosis in ATRA-resistant acute promyelocytic leukemia cells[J]. Leuke Res, 2008,32(1):143-149.
[11] Williams C R, Tabios R, Linehan W M, et al. Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model[J]. J Urol, 2007,178(4 pt 1):1528-1532.
[12] Chung Y L, Troy H, Ronen U, et al. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin(17-AAG) in human colon cancer models[J]. J Natl Cancer Inst, 2003,95(21):1624-1633.
[13] 肖丽君,赵恩宏,赵爽,等.17-AAG对MCF-7细胞增殖的抑制作用及对STAT3和VEGF表达的影响[J].中国医科大学学报,2013,42(1):65-68.

Preparation and anti-tumor activity of a novel liposome-loaded drug

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 6

Recommended Articles

Metrics

Comments

[1]	Li Feiyang, Cui Chunying, Wang Yuji, Wu Jianhui. Preparation and antitumor activity of a novel liposome of doxorubicin [J]. Journal of Capital Medical University, 2015, 36(2): 157-160.
[2]	Wei Liyan, Cui Chunying, Wu Jianhui, Wang Yuji. Preparation and anti-tumor bioassays of lipid emulsion composed of seal oil as a drug delivery system for docetaxel [J]. Journal of Capital Medical University, 2015, 36(2): 192-198.
[3]	Yan Yan, Wang Yuji, Wu Jianhui, Cui Chunying. Studies on anticancer activity of 17-AAG poly-butylcyanoacrylate nanoparticles [J]. Journal of Capital Medical University, 2015, 36(2): 178-184.
[4]	Shi Fan, Cui Chunying, Wu Jianhui, Wang Yuji. Evaluation of anti-tumor activity of docetaxel loaded nanostructured lipid carriers with seal oil [J]. Journal of Capital Medical University, 2015, 36(2): 185-191.
[5]	XU Yan-xia;ZHAO Ming;WANG Yu-ji;WU Jian-hui;LI Li;ZHANG Jian-wei;KANG Gui-feng;PENG Shi-qi. Discovery of Lead Pseudopeptides for Drug Design [J]. Journal of Capital Medical University, 2010, 31(5): 614-622.
[6]	Li Jinfeng;Zhang Zhenyu;Wang Shuzhen;Liu Jinwei. The Anti-tumor Immunity and Cultivation of the Fused Cells of Ovarian Cancer and Dendritic Cells Derived from Cord Blood——An In-vitro Study [J]. Journal of Capital Medical University, 2007, 28(5): 604-608.